Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report

被引：14

作者：

Cimpeanu, Emanuela ^{[1
]}

Ahmed, Jibran ^{[2
]}

Zafar, Wahib ^{[2
]}

DeMarinis, Adreana ^{[1
]}

Bardarov, Svetoslav S. ^{[3
]}

Salman, Shamim ^{[4
]}

Bloomfield, Dennis ^{[1
,5
]}

机构：

[1] Richmond Univ, Dept Internal Med, Med Ctr, 355 Bard Ave, Staten Isl, NY 10310 USA

[2] Westchester Med Ctr, Dept Hematol & Med Oncol, Valhalla, NY 10595 USA

[3] Richmond Univ, Dept Pathol, Med Ctr, Staten Isl, NY 10310 USA

[4] Richmond Univ, Dept Hematol & Med Oncol, Med Ctr, Staten Isl, NY 10310 USA

[5] Richmond Univ, Dept Clin Res, Med Ctr, Staten Isl, NY 10310 USA

来源：

WORLD JOURNAL OF CLINICAL CASES | 2020年 / 8卷 / 01期

关键词：

Pembrolizumab; Pulmonary sarcomatoid carcinoma; Programmed death-ligand 1; Platinum-based chemotherapy; Non-small-cell lung cancer; Overall survival; Case report; CELL LUNG-CANCER; PLEOMORPHIC CARCINOMA; CHEMOTHERAPY; EFFICACY;

D O I：

10.12998/wjcc.v8.i1.97

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma (PSC), a rare, previously rapidly fatal subtype of non-small-cell lung cancer. CASE SUMMARY We report the case of a 69-year-old man presented with respiratory distress caused by a large left upper lung lobe mass diagnosed as PSC with programmed death-ligand 1 expressed on more than 50 percent of tumor cells. The patient was started on pembrolizumab and, after 5 cycles, there was a more than 80 percent decrease in the size of the tumor mass. Further decrease was seen at the end of 10 cycles. The patient has been tolerating pembrolizumab well, with no limiting side-effects. Fourteen months after first coming into the hospital, he remains asymptomatic. CONCLUSION Pembrolizumab appears as a viable emerging treatment for PSC.

引用

页码：97 / 102

页数：6

共 18 条

[1] Pulmonary sarcomatoid carcinoma [J].

Antoine, Martine ;

Vieira, Thibault ;

Fallet, Vincent ;

Hamard, Cecile ;

Duruisseaux, Michael ;

Cadranel, Jacques ;

Wislez, Marie .

ANNALES DE PATHOLOGIE, 2016, 36 (01) :44-54

[2] EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics [J].

Arcila, Maria E. ;

Nafa, Khedoudja ;

Chaft, Jamie E. ;

Rekhtman, Natasha ;

Lau, Christopher ;

Reva, Boris A. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Ladanyi, Marc .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) :220-229

[3] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[4] Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1 [J].

Ikematsu, Yuki ;

Yoneshima, Yasuto ;

Ijichi, Kayo ;

Tanaka, Kentaro ;

Harada, Taishi ;

Oda, Yoshinao ;

Nakanishi, Yoichi ;

Okamoto, Isamu .

LUNG CANCER, 2017, 112 :230-231

[5] Pulmonary sarcomatoid carcinoma: University of Cincinnati experience [J].

Karim, Nagla Abdel ;

Schuster, James ;

Eldessouki, Ihab ;

Gaber, Ola ;

Namad, Tariq ;

Wang, Jiang ;

Xie, Changchun ;

Morris, John C. .

ONCOTARGET, 2018, 9 (03) :4102-4108

[6] Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study [J].

Langer, Corey J. ;

Gadgeel, Shirish M. ;

Borghaei, Hossein ;

Papadimitrakopoulou, Vassiliki A. ;

Patnaik, Amita ;

Powell, Steven F. ;

Gentzler, Ryan D. ;

Martins, Renato G. ;

Stevenson, James P. ;

Jalal, Shadia I. ;

Panwalkar, Amit ;

Yang, James Chih-Hsin ;

Gubens, Matthew ;

Sequist, Lecia V. ;

Awad, Mark M. ;

Fiore, Joseph ;

Ge, Yang ;

Raftopoulos, Harry ;

Gandhi, Leena .

LANCET ONCOLOGY, 2016, 17 (11) :1497-1508

[7] PD-1 Blockade in Tumors with Mismatch-Repair Deficiency [J].

Le, D. T. ;

Uram, J. N. ;

Wang, H. ;

Bartlett, B. R. ;

Kemberling, H. ;

Eyring, A. D. ;

Skora, A. D. ;

Luber, B. S. ;

Azad, N. S. ;

Laheru, D. ;

Biedrzycki, B. ;

Donehower, R. C. ;

Zaheer, A. ;

Fisher, G. A. ;

Crocenzi, T. S. ;

Lee, J. J. ;

Duffy, S. M. ;

Goldberg, R. M. ;

de la Chapelle, A. ;

Koshiji, M. ;

Bhaijee, F. ;

Huebner, T. ;

Hruban, R. H. ;

Wood, L. D. ;

Cuka, N. ;

Pardoll, D. M. ;

Papadopoulos, N. ;

Kinzler, K. W. ;

Zhou, S. ;

Cornish, T. C. ;

Taube, J. M. ;

Anders, R. A. ;

Eshleman, J. R. ;

Vogelstein, B. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2509-2520

[8] Characteristics and Prognostic Analysis of 69 Patients With Pulmonary Sarcomatoid Carcinoma [J].

Lin, Yongbin ;

Yang, Han ;

Cai, Qingqing ;

Wang, Daofeng ;

Rao, Huilan ;

Lin, Suxia ;

Long, Hao ;

Fu, Jianhua ;

Zhang, Lanjun ;

Lin, Peng ;

Xu, Guangchuan ;

Rong, Tiehua ;

Xiong, Xiaoxing ;

Ma, Guowei ;

Liang, Ying .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (03) :215-222

[9]

Matsumoto Y, 2017, CASE REP ONCOL, V10, P752, DOI 10.1159/000479552

[10] Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review [J].

Palka Kotlowska, Magda ;

Gomez Rueda, Ana ;

Eugenia Olmedo, Maria ;

Benito, Amparo ;

Santon Roldan, Almudena ;

Fernandez Mendez, Maria Angeles ;

Gorospe, Luis ;

Palacios, Jose ;

Garrido Lopez, Pilar .

RESPIRATORY MEDICINE CASE REPORTS, 2019, 26 :310-314

← 1 2 →